SAFINAMIDE MESYLATE
Safinamide mesylate is indicated as an adjunctive treatment for patients with Parkinson’s disease. It is used specifically for individuals currently taking levodopa/carbidopa who are experiencing "off" episodes. The medication functions as a monoamine oxidase type B (MAO-B) inhibitor to provide supplemental therapy for managing these symptoms.
How SAFINAMIDE MESYLATE Works
Safinamide mesylate works by inhibiting the activity of monoamine oxidase B (MAO-B). By blocking this enzyme, the drug prevents the catabolism, or breakdown, of dopamine in the brain. This inhibition leads to an increase in dopamine levels and a subsequent rise in dopaminergic activity.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2023-06-14
- Routes
- ORAL
- Dosage Forms
- TABLET
SAFINAMIDE MESYLATE Approval History
What SAFINAMIDE MESYLATE Treats
1 indicationsSAFINAMIDE MESYLATE is approved for 1 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Parkinson's Disease
SAFINAMIDE MESYLATE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to SAFINAMIDE MESYLATE
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
SAFINAMIDE MESYLATE FDA Label Details
Indications & Usage
SAFINAMIDE MESYLATE is indicated for the treatment of Parkinson's Disease.
Looking for the branded version?
XADAGO
Full clinical data, patents, trials, and competitive landscape for safinamide mesylate.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment